Neurodegenerative market to be worth $45 billion by 2022

pharmafile | December 12, 2016 | News story | Sales and Marketing Biogen, GBI Research, Novartis, Roche, Sanofi, neurodegenerative 

Neurodegenerative disorders including Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) form a lucrative worldwide market which is projected to rise in value to be worth $45 billion by 2022, up from $27.2 billion last year, according to new data form GBI Research.

The primary driving factor given for this growth is the expected approval of a number of pipeline products between 2018 and 2022 such as Roche’s ocrelizumab, which is expected to pull the company ahead of its rivals in the space.

“There is a large pharmaceutical pipeline for neurodegenerative disorders, consisting of approximately 1494 products in active development,” GBI Research analyst Qaisrah Khalid explained: “The majority of pipeline products are novel active pharmaceutical ingredients, with only a small proportion of products being either generics, or repositioned from other indications – most of which are at Phase I. This indicates progress in terms of different molecules being developed as therapeutic agents within the neurodegenerative pipeline.”

Khalid continued: “The revenue for the highest-selling product within the MS market – Copaxone (glatiramer acetate), marketed by Teva – is expected to decrease substantially following its 2014 patent expiry, from just over $4 billion in 2015 to $2.5 billion by 2022, owing to competition from generics, such as Glatopa. Declining revenues from this and other drugs will lead to a significant drop in the neurodegenerative disorder market share for Teva.”

Biogen, Novartis and Sanofi are expected to maintain their hold on the market despite impending patent expiries, the report added.

Matt Fellows

Related Content

Sanofi announce positive phase 2 data for MS drug frexalimab

French pharmaceutical and healthcare company Sanofi have announced positive trial data from its phase 2 …

Maze Therapeutics and Sanofi sign exclusive worldwide license agreement for Pompe disease treatment

Maze Therapeutics and Sanofi have announced that they have signed an exclusive worldwide license agreement …

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human …

Latest content